摘要目的目前,国内外尚未见有关可溶性细胞间粘附分子-1(sICAM-1)放免法 (RIA)的报道,为此用本室研制的125Ⅰ-sICAM-1 RIA,检测正常人和三种甲状腺疾病(单纯性甲肿,Graves'病或Hashimoto'病)患者血清sICAM-1水平.方法用125Ⅰ-sICAM-1 RIA,检测400例正常人以及1020例患有单纯性甲状腺肿、Graves'病或者Hashimoto'病患者血清sICAM-1水平.结果正常组sICAM-1水平(±s)为:168.43±36.23 μg/L.正常组与单纯性甲肿组间无显著性差别(P>0.05),而自身免疫性甲状腺疾病(Graves'病和Hashimoto' 病)均分别明显高于正常组或单纯性甲肿组(P<0.05).三种治疗均可降低Graves' 病患者血清sICAM-1水平(P<0.05).药物治疗后甲状腺功能恢复正常的Graves'病组 sICAM-1水平明显低于Graves'病停药复发组(P<0.05).结论 125Ⅰ-sICAM-1 RIA可用于检测自身免疫性甲状腺疾病;血清sICAM-1水平可作为自身免疫性甲状腺疾病诊断的一个指标,及在评价Graves'病的疗效、停药或者复发等方面的一个指标.

abstractsObjective To examine serum levels of sICAM-1 from normal controls and patients with thyroid diseases (simple goitre, Graves' disease or Hashimoto'sthyroiditis) with 125Ⅰ-sICAM-1 RIA established in our lab.Methods Using 125Ⅰ-sICAM-1 RIA, serum sICAM-1 levels of 400 healthy in dividuals as the normal group and 1020 patients with simple goitre (SG), Graves' disease (GD) or Hashimoto's thyroiditis (HT) were examined for a comporative chinical study.Conclusions sICAM-1 RIA can be used to examine autoimmune thyroid diseases. Serum levels of sICAM-1 can be used as a parameter in diagnosing autoimmune thyroid disease and in evaluating the effects of therapy, drug administration or relapse in GD.